Sotrastaurin

Drug Profile

Sotrastaurin

Alternative Names: AEB 071; NVP-AEB071; Sotrastaurin acetate

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis; Ohio State University
  • Developer Novartis
  • Class Piperazines; Pyrroles; Quinazolines; Small molecules
  • Mechanism of Action Immunosuppressants; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma; Uveal melanoma
  • Discontinued Liver transplant rejection; Psoriasis; Renal transplant rejection; Transplant rejection; Ulcerative colitis; Uveitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Uveal-melanoma(Metastatic disease) in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma in Spain (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top